Investors

Home / Investors / Press Releases
10Nov

CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City

10Nov

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis

9Nov

CymaBay Reports Third Quarter 2016 Financial Results

9Nov

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)

2Nov

CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9

20Oct

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting

20Oct

CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis

11Oct

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

6Oct

CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting

5Oct

CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis